Drugs / Allogeneic Mesenchymal Precursor Cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01851070 Comparator | Jul 2013 → May 2016 | rheumatoid arthritis | Mesoblast, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Mesenchymal Precursor Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01851070 ↗ |
| Known as | MPCs | “Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.” NCT01851070 ↗ |
| Route | Intravenous | “administered intravenously” NCT01851070 ↗ |